1 |
Park YK, Park YS, Na KI, Cho EH, Shin SS, Kim HJ. Increased tuberculosis burden due to demographic transition in Korea from 2001 to 2010. Tuberc Respir Dis 2013;74:104-10.
DOI
ScienceOn
|
2 |
Joint Committee for the Development of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. Seoul: Joint Committee for the Development of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention; 2011.
|
3 |
Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62.
DOI
ScienceOn
|
4 |
World Health Organization. Treatment of tuberculosis guideline. 4th ed. Geneva: World Health Organization; 2010.
|
5 |
Park WB, Kim W, Lee KL, Yim JJ, Kim M, Jung YJ, et al. Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis. J Infect 2010;61:323-9.
DOI
|
6 |
British Thoracic Society Standards of Care Committee and Joint Tuberculosis Committee, Milburn H, Ashman N, Davies P, Doffman S, Drobniewski F, et al. Guidelines for the pre-vention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax 2010;65:557-70.
DOI
|
7 |
Subramanian AK, Morris MI; AST Infectious Diseases Community of Practice. Mycobacterium tuberculosis infections in solid organ transplantation. Am J Transplant 2013;13 Suppl 4:68-76.
DOI
|
8 |
Kim DK, Lee SW, Yoo CG, Kim YW, Han SK, Shim YS, et al. Clinical characteristics and treatment responses of tuberculosis in patients with malignancy receiving anticancer chemotherapy. Chest 2005;128:2218-22.
DOI
ScienceOn
|
9 |
Lee BH, Koh WJ, Choi MS, Suh GY, Chung MP, Kim H, et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005;127:1304-11.
DOI
|